Topical application of cannabinoid-ligands ameliorates experimental dry-eye disease

Abstract Purpose Dry eye disease (DED) is a multifactorial disease, with limitations regarding efficacy and tolerability of applied substances. Among several candidates, the endocannabinoid system with its receptors

January 15, 2024

Tolerance to the Memory Disruptive Effects of Cannabinoids Involves Adaptation by Hippocampal Neurons

The effects of chronic exposure to cannabinoids on short-term memory in rats were assessed during repeated daily injections of an initially debilitating dose (3.75 mg/kg)

September 19, 2019

Tolerance for specific negative affective states and coping-oriented cannabis use motives among college student cannabis users

Please use this link to access this publication. Abstract Objective The current study examined the unique predictive ability of tolerance of specific negative affective states

March 14, 2024

Tolerability of High-Dose Oral Δ9-THC: Implications for Human Laboratory Study Design

Please use this link to access this publication. Abstract Background: Δ9-tetrahydrocannabinol (THC), the primary intoxicating compound in cannabis, has been tested extensively in controlled administration human

March 13, 2024

Tissue Engineering of Cartilage; Can Cannabinoids Help?

This review discusses the role of the cannabinoid system in cartilage tissue and endeavors to establish if targeting the cannabinoid system has potential in mesenchymal

September 19, 2019

Time to onset of cannabidiol treatment effects in Dravet syndrome: Analysis from two randomized controlled trials

Abstract Objective We conducted a post hoc analysis of two randomized controlled trials, GWPCARE1 (NCT02091375) and GWPCARE2 (NCT02224703), to estimate the time to onset of

April 23, 2024

Time to onset of cannabidiol treatment effect and resolution of adverse events in tuberous sclerosis complex: Post hoc analysis of randomized controlled phase 3 trial GWPCARE6

Abstract Objective To estimate the timing of cannabidiol (CBD) treatment effect (seizure reduction and adverse events [AEs]) onset, we conducted a post hoc analysis of

January 18, 2024

Time to onset of cannabidiol (CBD) treatment effect in Lennox–Gastaut syndrome: Analysis from two randomized controlled trials

Abstract Objective To estimate time to onset of cannabidiol (CBD) treatment effect (seizure reduction and adverse events [AEs]), we conducted post hoc analyses of data

April 1, 2024

Thymol modulates the endocannabinoid system and gut chemosensing of weaning pigs

Abstract   Background The recent identification of the endocannabinoid system in the gastrointestinal tract suggests a role in controlling intestinal inflammation. In addition, the gut

September 14, 2023

Thymol has beneficial effects on the experimental model of ulcerative colitis

Abstract   Objective: Thymol, a natural aromatic monoterpene phenol derived from thymus, possesses anti-inflammatory benefits. Here, we evaluated the potential of thymol therapy in improving an